Company intelligence / Profile preview

Biotectid

Ownership: Private
Development stage: Preclinical

Overview

BIOTECTID is a biotech company founded around 2000 that conducts research in immunology and develops biopharmaceuticals for molecular imaging. The company received a European patent related to an in vivo diagnostic platform as of 2009. No recent clinical results are available.[1]

Therapeutic areas: Other
Modalities: Molecular imaging agentsLikely biologics or diagnostic antibodies (inferred from immunology and molecular imaging focus)[1]
Industry: Medical Imaging

Drug pipeline

1 asset

EP1645

Pre-clinical

Indications: Rheumatoid arthritis, High-risk atherosclerosis

Beyond the preview

Go deeper on Biotectid.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotectid.

Explore the full profile